Literature DB >> 19562799

Comprehensive proteomic and transcriptomic analysis reveals early induction of a protective anti-oxidative stress response by low-dose proteasome inhibition.

Sven Bieler1, Silke Meiners, Verena Stangl, Thomas Pohl, Karl Stangl.   

Abstract

Effective inhibition of the proteasome by high doses of proteasome inhibitors induces apoptotic cell death. In contrast, partial proteasome inhibition by low inhibitor doses mediates a protective cellular stress response. The early targets and mediators of these dose-dependent effects of proteasome inhibitors are unknown. Primary human umbilical cord vein endothelial cells were treated with low and high doses of the proteasome inhibitor MG132 for 2 h. In a combined 2-DE and MS approach, we identified more than 20 new targets of proteasome inhibition. These proteins are involved in cell cycle regulation, signaling, cytoskeletal rearrangement, and cellular stress response. Accompanying Affymetrix analysis revealed that these proteins are not regulated on the transcriptional level but are mainly stabilized by proteasome inhibition. The proteasome-dependent accumulation of the anti-oxidative sensor proteins DJ-1, peroxiredoxin-1 and -6 was accompanied by dose-dependent induction of oxidative stress after 2 h of proteasome inhibition and contributed to the differential transcriptional stress response to low- and high-dose proteasome inhibition: Whereas low-dose proteasome inhibition induces a transcriptional profile reminiscent of a physiological stress response that preconditions and protects endothelial cells from oxidative stress, high inhibitor doses induce massive transcriptional dysregulation and pronounced oxidative stress triggering apoptosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19562799     DOI: 10.1002/pmic.200800927

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  12 in total

1.  PAC1 gene knockout reveals an essential role of chaperone-mediated 20S proteasome biogenesis and latent 20S proteasomes in cellular homeostasis.

Authors:  Katsuhiro Sasaki; Jun Hamazaki; Masato Koike; Yuko Hirano; Masaaki Komatsu; Yasuo Uchiyama; Keiji Tanaka; Shigeo Murata
Journal:  Mol Cell Biol       Date:  2010-05-24       Impact factor: 4.272

Review 2.  The ubiquitin-proteasome system and cardiovascular disease.

Authors:  Saul R Powell; Joerg Herrmann; Amir Lerman; Cam Patterson; Xuejun Wang
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

3.  Proteasome inhibitor up regulates liver antioxidative enzymes in rat model of alcoholic liver disease.

Authors:  Fawzia Bardag-Gorce; Joan Oliva; Andrew Lin; Jun Li; Barbara A French; Samuel W French
Journal:  Exp Mol Pathol       Date:  2010-10-29       Impact factor: 3.362

4.  Statistical approach to protein quantification.

Authors:  Sarah Gerster; Taejoon Kwon; Christina Ludwig; Mariette Matondo; Christine Vogel; Edward M Marcotte; Ruedi Aebersold; Peter Bühlmann
Journal:  Mol Cell Proteomics       Date:  2013-11-19       Impact factor: 5.911

Review 5.  Dysfunction of the ubiquitin-proteasome system in atherosclerotic cardiovascular disease.

Authors:  Feilong Wang; Amir Lerman; Joerg Herrmann
Journal:  Am J Cardiovasc Dis       Date:  2015-03-10

Review 6.  Venous and arterial endothelial proteomics: mining for markers and mechanisms of endothelial diversity.

Authors:  Matthew R Richardson; Xianyin Lai; Frank A Witzmann; Mervin C Yoder
Journal:  Expert Rev Proteomics       Date:  2010-12       Impact factor: 3.940

7.  Proteomic analysis of MG132-treated germinating pollen reveals expression signatures associated with proteasome inhibition.

Authors:  Candida Vannini; Marcella Bracale; Rita Crinelli; Valerio Marconi; Paola Campomenosi; Milena Marsoni; Valeria Scoccianti
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

8.  Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis.

Authors:  Nora Semren; Nunja C Habel-Ungewitter; Isis E Fernandez; Melanie Königshoff; Oliver Eickelberg; Tobias Stöger; Silke Meiners
Journal:  PLoS One       Date:  2015-09-04       Impact factor: 3.240

9.  The proteasome inhibitor, MG132, attenuates diabetic nephropathy by inhibiting SnoN degradation in vivo and in vitro.

Authors:  Wei Huang; Chen Yang; Qinling Nan; Chenlin Gao; Hong Feng; Fang Gou; Guo Chen; Zhihong Zhang; Pijun Yan; Juan Peng; Yong Xu
Journal:  Biomed Res Int       Date:  2014-06-09       Impact factor: 3.411

10.  Abrogation of Nrf2 impairs antioxidant signaling and promotes atrial hypertrophy in response to high-intensity exercise stress.

Authors:  Radhakrishnan Rajesh Kumar; Madhusudhanan Narasimhan; Gobinath Shanmugam; Jennifer Hong; Asokan Devarajan; Sethu Palaniappan; Jianhua Zhang; Ganesh V Halade; Victor M Darley-Usmar; John R Hoidal; Namakkal S Rajasekaran
Journal:  J Transl Med       Date:  2016-04-05       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.